Clinical phase I/II studies with the Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec,
formerly STI571) for the treatment for chronic myelogenous leukemia (CML) demonstrated …

Imatinib mesylate (Gleevec™, Glivec®, formerly STI571; Novartis Pharmaceuticals) is an
inhibitor of the Bcr-abl tyrosine kinase that is central to the pathogenesis of chronic myeloid …

Treatment options for chronic myeloid leukemia (CML) have changed dramatically during
the last decades. Interferon-α treatment and stem cell transplantation (SCT) clearly improved …

Summary Abstract Imatinib (Gleevec®, Glivec®) is a synthetic tyrosine kinase inhibitor used
in the treatment of chronic myeloid leukaemia (CML). It is specifically designed to inhibit the …

Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …

Chronic myeloid leukemia (CML) is a malignant disease that originates in the bone marrow
and is designated by the presence of the Philadelphia (Ph+) chromosome, a translocation …

The Bcr-Abl tyrosine kinase inhibitor imatinib (Glivec®, formerly STI571, Novartis Pharma
AG, Basel, Switzerland) produces complete hematologic and cytogenetic responses in a …

Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …

In this article, the authors briefly recap the key clinical trials that involve imatinib mesylate
(Gleevec, Glivec, STI571). Because the reader may be familiar with many of these …

The tyrosine kinase inhibitor Imatinib Mesylate has dramatically improved the clinical
outcome of chronic myeloid leukemia (CML) patients in the chronic phase of the disease …